Most common Form 483 observations at 503B outsourcing facilities
What are the most common FDA Form 483 observations at 503B outsourcing facilities?
Across 186 Form 483s whose cover gives the establishment as an outsourcing facility (79 facilities with pages here, inspections ending Mar 27, 2014 to Sep 23, 2026), the most common observation themes are sterility assurance and aseptic processing (362 of 1,210 observations, in 155 of the 186 483s), laboratory testing and release (306 of 1,210 observations, in 137 of the 186 483s) and equipment, buildings and facilities (172 of 1,210 observations, in 107 of the 186 483s). The single statement FDA wrote most often is “Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.” (70 times).
Themes come from a fixed keyword rule applied to FDA’s one-line statement of each observation, printed below. A 483 lists an investigator’s observations and is not a final FDA determination.
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
Observations by theme
| Sterility assurance and aseptic processing | 362 | 30% | 155 of 186 |
| Laboratory testing and release | 306 | 25% | 137 of 186 |
| Equipment, buildings and facilities | 172 | 14% | 107 of 186 |
| Components, containers and closures | 144 | 12% | 96 of 186 |
| Production and process controls, validation | 138 | 11% | 93 of 186 |
| Cleaning, sanitizing and disinfection | 120 | 10% | 95 of 186 |
| Investigations and complaints | 112 | 9% | 97 of 186 |
| Other | 106 | 9% | 74 of 186 |
| Records and documentation | 94 | 8% | 71 of 186 |
| Environmental and personnel monitoring, air quality | 93 | 8% | 80 of 186 |
| Quality control unit | 90 | 7% | 78 of 186 |
| Labeling | 78 | 6% | 64 of 186 |
| Personnel, training and gowning | 65 | 5% | 59 of 186 |
| Stability and expiration or beyond-use dating | 45 | 4% | 42 of 186 |
| Cross-contamination and hazardous drugs | 26 | 2% | 25 of 186 |
The rule
Each observation on a 483 opens with a one-line statement, usually followed by “Specifically,” and the details. The rule reads only that statement (the text before “Specifically” or its first sentence) and counts the observation under every theme below whose pattern matches, ignoring case. An observation that matches none counts as Other. The patterns are regular expressions; \b marks a word boundary.
| Theme | Counted when the lead sentence matches any of |
|---|---|
| Sterility assurance and aseptic processing | steril aseptic microbiological contamination objectionable microorganisms media fills? endotoxin pyrogen |
| Environmental and personnel monitoring, air quality | environmental (monitoring|conditions) monitoring environmental personnel monitoring \bair (pressure|flow|quality|supply|filtration) \bairflow pressure differential smoke stud \bHEPA\b dynamic conditions |
| Cleaning, sanitizing and disinfection | \bclean(ed|ing|s)?\b saniti[sz] disinfect sporicid |
| Equipment, buildings and facilities | \bequipment\b \butensils\b \bbuildings?\b (appropriate|adequate|suitable) (size|design|construction) \bmaintenance\b \bcalibrat \bfacilities\b |
| Quality control unit | quality control unit \bquality unit\b |
| Investigations and complaints | investigat discrepanc complaints?\b out[- ]of[- ]specification \bdeviations?\b |
| Laboratory testing and release | \btest(s|ed|ing)?\b \blaborator(y|ies)\b \bpotency\b \bspecifications?\b \breleased?\b \bassay |
| Stability and expiration or beyond-use dating | stability expiration beyond[- ]use \bBUDs?\b |
| Production and process controls, validation | production and process control \bvalidat \bmaster (production|formula) \bbatch production\b |
| Records and documentation | \brecords?\b \bdocument(ed|ation)?\b |
| Labeling | \blabel |
| Components, containers and closures | \bcomponents?\b bulk drug substances? active pharmaceutical ingredient containers? and closures? container[- ]closure |
| Personnel, training and gowning | \btrain(ing|ed)\b \bgown protective apparel \bpersonnel\b \bemployees?\b |
| Cross-contamination and hazardous drugs | cross[- ]contamination hazardous mix-?ups? segregat containment penicillin|beta-lactam |
| Other | None of the above |
The statements FDA wrote most often
The same one-line statements recur because investigators draw them from FDA’s drug manufacturing regulations. These are the 20 most frequent, word for word, across the same 186 483s.
| Aseptic processing areas are deficient regarding the system for monitoring environmental conditions. | 70 | 70 |
| Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions. | 36 | 36 |
| There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed. | 33 | 33 |
| : Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written, and followed. | 31 | 31 |
| The responsibilities and procedures applicable to the quality control unit are not fully followed. | 20 | 20 |
| : The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed. | 19 | 19 |
| There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed. | 17 | 17 |
| The labels of your outsourcing facility's drug products are deficient. | 15 | 15 |
| Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process. | 14 | 14 |
| Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed. | 13 | 13 |
| Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release. | 13 | 13 |
| Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess. | 13 | 13 |
| Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure. | 12 | 12 |
| Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions. | 12 | 12 |
| Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process. | 12 | 12 |
| There is no written testing program designed to assess the stability characteristics of drug products. | 11 | 11 |
| Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed. | 10 | 10 |
| Your outsourcing facility did not submit a report to FDA identifying the drugs compounded during the previous six month period. | 10 | 10 |
| There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed. | 9 | 9 |
| Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel. | 8 | 8 |
The 483s counted
- Sep 23, 2026: LEESAR, INC., 9 observations. PDF
- Sep 8, 2026: Right Value Drug Stores LLC, 6 observations. PDF
- Sep 3, 2026: OPS International Inc dba Olympia Pharmaceuticals, 8 observations. PDF
- Sep 3, 2026: RC Outsourcing, LLC, 8 observations. PDF
- Aug 28, 2026: Tailstorm Health, Inc, 5 observations. PDF
- Aug 19, 2026: STAQ Pharma of Ohio, LLC, 3 observations. PDF
- Aug 12, 2026: OurPharma LLC, 3 observations. PDF
- Aug 12, 2026: IntegraDose Compounding Services LLC, 4 observations. PDF
- Jul 28, 2026: Apollo Care, LLC, 7 observations. PDF
- Jul 10, 2026: Brookfield Medical/Surgical Supplies, I nc., 3 observations. PDF
- Jun 3, 2026: Annovex Pharma, Inc., 2 observations. PDF
- Jun 1, 2026: PQ Pharmacy LLC, 7 observations. PDF
- May 29, 2026: Sincerus Florida, LLC dba SKNV, 7 observations. PDF
- May 7, 2026: Turbare Manufacturing, 4 observations. PDF
- May 4, 2026: QuVa Pharma, Inc., 3 observations. PDF
- Apr 17, 2026: BPI Labs, LLC, 4 observations. PDF
- Apr 13, 2026: Wells Pharma of Houston LLC, 6 observations. PDF
- Apr 9, 2026: Wells Pharmacy, Inc, 2 observations. PDF
- Mar 13, 2026: SCA Pharmaceuticals, LLC, 3 observations. PDF
- Mar 12, 2026: BayCare Integrated Service Center LLC, 9 observations. PDF
- Dec 19, 2025: F.H. Investments, Inc. (dba Asteria Health), 10 observations. PDF
- Dec 11, 2025: Nubratori, Inc, 3 observations. PDF
- Dec 11, 2025: Denver Solutions, LLC, 7 observations. PDF
- Nov 21, 2025: Delta Pharma, Inc., 2 observations. PDF
- Nov 14, 2025: Tailstorm Health Inc dba Medivant Health, 3 observations. PDF
- Nov 14, 2025: OSRX Inc., 4 observations. PDF
- Nov 10, 2025: Empower Clinic Services, L.L.C. dba Empower Pharma, 9 observations. PDF
- Nov 5, 2025: Fresenius Kabi Compounding, LLC, 7 observations. PDF
- Sep 5, 2025: Central Admixture Pharmacy Services, Inc., 8 observations. PDF
- Sep 5, 2025: Central Admixture Pharmacy Services, Inc., 5 observations. PDF
- Sep 5, 2025: FARMAKEIO OUTSOURCING LLC, 5 observations. PDF
- Sep 4, 2025: Qualgen, LLC, 5 observations. PDF
- Aug 28, 2025: RC Outsourcing, LLC, 8 observations. PDF
- Aug 11, 2025: Molecular PharmaGroup LLC, 3 observations. PDF
- Aug 8, 2025: Hikma Injectables USA Inc., 4 observations. PDF
- Aug 8, 2025: AnazaoHealth Corporation, 4 observations. PDF
- Aug 8, 2025: Olympia Pharmaceuticals, 3 observations. PDF
- Aug 8, 2025: Fagron Compounding Services, 6 observations. PDF
- Jul 25, 2025: IntegraDose Compounding Services LLC, 6 observations. PDF
- Jul 18, 2025: Right Value Drug Stores LLC, 5 observations. PDF
- Jul 16, 2025: BSO LLC, 9 observations. PDF
- Jun 27, 2025: BSO, LLC, 8 observations. PDF
- Jun 10, 2025: MedisourceRx, 2 observations. PDF
- May 23, 2025: Tailstorm Health, Inc. dba Medivant Healthcare, 5 observations. PDF
- May 16, 2025: STAQ Pharma of Ohio, LLC, 3 observations. PDF
- May 15, 2025: Apothecary Pharma LLC, 8 observations. PDF
- May 9, 2025: LEESAR, INC, 4 observations. PDF
- Apr 4, 2025: QuVa Pharma, Inc., 5 observations. PDF
- Apr 4, 2025: PQ Pharmacy LLC, 4 observations. PDF
- Mar 27, 2025: Apollo Care, LLC, 6 observations. PDF
- Mar 6, 2025: SKNV, 3 observations. PDF
- Feb 21, 2025: BPI Labs LLC, 1 observation. PDF
- Jan 24, 2025: Turbare Manufacturing, 8 observations. PDF
- Dec 20, 2024: SCA Pharmaceuticals, LLC, 7 observations. PDF
- Nov 15, 2024: Exela Pharma Sciences LLC, 15 observations. PDF
- Nov 8, 2024: F.H. I nvestments Inc., 5 observations. PDF
- Oct 28, 2024: QuVa Pharma, Inc., 4 observations. PDF
- Oct 25, 2024: OSRX Inc., 6 observations. PDF
- Sep 30, 2024: Pine Pharmaceuticals, LLC, 9 observations. PDF
- Sep 27, 2024: RC Outsourcing, LLC, 8 observations. PDF
- Sep 27, 2024: OurPharma LLC, 5 observations. PDF
- Sep 26, 2024: Staska Pharmaceuticals Inc., 9 observations. PDF
- Sep 6, 2024: Annovex Pharma, Inc., 7 observations. PDF
- Sep 6, 2024: Mark Cuban Cost Plus Manufacturing and Compounding LLC, 7 observations. PDF
- Aug 28, 2024: Empower Pharmacy, 9 observations. PDF
- Aug 16, 2024: Belcher Pharmaceuticals, LLC, 6 observations. PDF
- Aug 2, 2024: ProRx LLC, 13 observations. PDF
- Jul 26, 2024: Nubratori, Inc, 7 observations. PDF
- Jul 3, 2024: BSO LLC, 5 observations. PDF
- Jun 28, 2024: Fagron Compounding Services, LLC dba Fagron Sterile Services, 7 observations. PDF
- Jun 25, 2024: Hikma Injectables USA Inc., 4 observations. PDF
- Jun 12, 2024: Hikma Pharmaceuticals USA Inc., 3 observations. PDF
- May 23, 2024: SKNV, 2 observations. PDF
- Apr 12, 2024: Delta Pharma, Inc., 3 observations. PDF
- Mar 19, 2024: Qualgen, LLC, 14 observations. PDF
- Mar 1, 2024: IntegraDose Compounding Services LLC, 8 observations. PDF
- Feb 8, 2024: SSM Health Care St. Louis DBA SSM St. Clare Health Center, 10 observations. PDF
- Nov 17, 2023: Wedgewood Connect, LLC, 8 observations. PDF
- Oct 20, 2023: SCA Pharmaceuticals, LLC, 10 observations. PDF
- Oct 4, 2023: STAQ Pharma of Ohio, LLC, 2 observations. PDF
- Sep 19, 2023: Pine Pharmaceuticals, LLC, 7 observations. PDF
- Jun 2, 2023: Delta Pharma, Inc., 1 observation. PDF
- May 26, 2023: Medi-Fare Drug, 4 observations. PDF
- Mar 30, 2023: Central Admixture Pharmacy Services, Inc., 6 observations. PDF
- Mar 6, 2023: Fresenius Kabi Compounding, LLC, 2 observations. PDF
- Mar 3, 2023: Prisma Health Outsourcing Facility, 4 observations. PDF
- Dec 14, 2022: Wells Pharma of Houston LLC, 3 observations. PDF
- Oct 27, 2022: PQ Pharmacy LLC, 7 observations. PDF
- Oct 27, 2022: PQ Pharmacy LLC, 7 observations. PDF
- Oct 14, 2022: QuVa Pharma, Inc., 5 observations. PDF
- Sep 23, 2022: RC Outsourcing LLC, 10 observations. PDF
- Sep 16, 2022: Athenex Pharma Solutions, LLC, 1 observation. PDF
- Aug 18, 2022: QuVa Pharma, Inc., 3 observations. PDF
- Aug 5, 2022: Empower Clinic Services LLC dba Empower Pharmacy, 17 observations. PDF
- Jun 27, 2022: Right Value Drug Stores, LLC dba Carie Boyd's Prescription Shop, 10 observations. PDF
- Jun 16, 2022: QuVa Pharma, Inc., 4 observations. PDF
- Jun 10, 2022: FARMAKEIO OUTSOURCING LLC, 7 observations. PDF
- Jun 8, 2022: Hikma Injectables USA Inc, 3 observations. PDF
- May 20, 2022: Delta Pharma, Inc., 5 observations. PDF
- Apr 28, 2022: New England Life Care, Inc. dba Advanced Compounding Solutions, 7 observations. PDF
- Apr 26, 2022: US Specialty Formulations LLC, 17 observations. PDF
- Apr 13, 2022: , 1 observation. PDF
- Apr 4, 2022: Brookfield Medical/Surgical Supply, Inc., 5 observations. PDF
- Mar 24, 2022: Fagron Compounding Services, 6 observations. PDF
- Mar 2, 2022: Olympia Compounding Pharmacy dba Olympia Pharmacy, 13 observations. PDF
- Feb 25, 2022: Central Admixture Pharmacy Services, Inc., 6 observations. PDF
- Dec 17, 2021: Compound Preferred LLC, 7 observations. PDF
- Dec 3, 2021: Wedgewood Connect, LLC, 4 observations. PDF
- Oct 29, 2021: LEESAR, INC, 5 observations. PDF
- Oct 7, 2021: Denver Solutions, LLC DBA Leiters Health, 7 observations. PDF
- Sep 30, 2021: OurPharma LLC, 2 observations. PDF
- Sep 28, 2021: SSM Healt h Care St. Louis DBA SSM St. Clare Health Center, 4 observations. PDF
- Sep 8, 2021: Apollo Care, LLC, 5 observations. PDF
- Sep 3, 2021: Hybrid Pharma LLC, 7 observations. PDF
- Aug 12, 2021: Eagle Pharmacy, Inc., 6 observations. PDF
- Aug 2, 2021: IntegraDose Compounding Services LLC, 4 observations. PDF
- Jul 21, 2021: TAILSTORM HEALTH INC, 4 observations. PDF
- Jun 17, 2021: Wells Pharma of Houston L LC, 1 observation. PDF
- May 21, 2021: Atlas Pharmaceuticals, LLC, 3 observations. PDF
- May 14, 2021: Pine Pharmaceuticals, LLC, 5 observations. PDF
- Apr 30, 2021: BPI Labs LLC, 3 observations. PDF
- Apr 29, 2021: Qualgen LLC, 15 observations. PDF
- Mar 11, 2021: BSO LLC, 4 observations. PDF
- Jan 28, 2021: Wells Pharmacy, Inc, 8 observations. PDF
- Oct 22, 2020: MedisourceRx, 7 observations. PDF
- Oct 9, 2020: Stokes Healthcare Inc. dba Epicur Pharma, 4 observations. PDF
- Sep 3, 2020: STAQ Pharma, Inc., 5 observations. PDF
- Mar 6, 2020: Empower Clinic Services, LLC, 6 observations. PDF
- Mar 4, 2020: AnazaoHealth Corporation, 9 observations. PDF
- Feb 28, 2020: Maitland Labs of Central Florida, 7 observations. PDF
- Dec 10, 2019: BAYCARE INTEGRATED SERVICE CENTER, 5 observations. PDF
- Nov 19, 2019: SCA Pharmaceuticals, 2 observations. PDF
- Nov 15, 2019: Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center, 9 observations. PDF
- Nov 12, 2019: Right Value Drug Stores, LLC dba Carie Boyd's Prescription Shop, 9 observations. PDF
- Oct 30, 2019: FARMAKEIO OUTSOURCING LLC, 3 observations. PDF
- Oct 18, 2019: Auro Pharmacies Inc, 11 observations. PDF
- Sep 26, 2019: Nubratori, Inc dba Nubratori Rx, 3 observations. PDF
- Sep 20, 2019: BSO LLC DBA Belmar Select Outsourcing, 2 observations. PDF
- Sep 19, 2019: AnazaoHealth Corporation, 3 observations. PDF
- Aug 28, 2019: SSM Health Care St. Louis DBA SSM St. Clare Health Center, 8 observations. PDF
- Aug 19, 2019: Athenex Pharma Solutions, LLC, 1 observation. PDF
- Aug 14, 2019: KRS Global Biotechnology, Inc, 14 observations. PDF
- Aug 1, 2019: RAM Pharma, Inc, 7 observations. PDF
- Jul 23, 2019: US Specialty Formulations LLC, 11 observations. PDF
- Jul 18, 2019: Denver Solutions, LLC DBA Leiter' s Health., 1 observation. PDF
- Jul 18, 2019: Exela Pharma Sciences LLC, 7 observations. PDF
- Jun 25, 2019: Infusion Options, Inc., 17 observations. PDF
- Jun 21, 2019: Fagron Compounding Services LLC dba Fagron Sterile Services, 11 observations. PDF
- Jun 20, 2019: Hybrid Pharma LLC, 11 observations. PDF
- Jun 17, 2019: Maitland Labs of Central Florida, 9 observations. PDF
- Jun 12, 2019: Premier Pharmacy Labs Inc, 16 observations. PDF
- Jun 6, 2019: RXQ Compounding LLC, 14 observations. PDF
- Apr 23, 2019: QuVa Pharma, Inc., 6 observations. PDF
- Mar 14, 2019: QuVaPharma. Inc., 9 observations. PDF
- Feb 7, 2019: US Compounding Inc, 10 observations. PDF
- Dec 19, 2018: Leiter's Enterprises, Inc., 3 observations. PDF
- Dec 10, 2018: Leiter's Enterprises, Inc., 3 observations. PDF
- Sep 27, 2018: MedisourceRx, 7 observations. PDF
- Sep 27, 2018: MedisourceRx, 7 observations. PDF
- Sep 19, 2018: , 6 observations. PDF
- Sep 17, 2018: Sincerus Florida, LLC, 6 observations. PDF
- Aug 28, 2018: Pharm D Solutions, LLC, 16 observations. PDF
- Jun 8, 2018: Delta Pharma, Inc., 9 observations. PDF
- Apr 26, 2018: Pine Pharma ce ut ica ls, LLC, 3 observations. PDF
- Apr 13, 2018: , 10 observations. PDF
- Dec 13, 2017: Athenex Pharma Solutions, LLC, 4 observations. PDF
- Nov 30, 2017: , 2 observations. PDF
- Sep 26, 2017: Atlas Pharmaceuticals, LLC, 11 observations. PDF
- Sep 20, 2017: Banner Pharmacy Services, LLC, 13 observations. PDF
- Sep 20, 2017: Banner Pharmacy Services, LLC, 13 observations. PDF
- Jun 29, 2017: Auro Pharmacies Inc, 13 observations. PDF
- Jun 1, 2017: , 7 observations. PDF
- May 10, 2017: Qualgen, LLC 14844 Bristol Park Blvd, 5 observations. PDF
- Mar 31, 2017: RC Outsourcing L LC, 9 observations. PDF
- Feb 7, 2017: , 13 observations. PDF
- Dec 2, 2016: , 16 observations. PDF
- Dec 2, 2016: Auro Pharmacies Inc 511 S Harbor Blvd Ste F, 16 observations. PDF
- Aug 31, 2016: California Pharmacy & Compounding Center, 5 observations. PDF
- Mar 12, 2016: QuVa Pharma, Inc., 5 observations. PDF
- Jan 4, 2016: Pharmedium Services, LLC, 6 observations. PDF
- Dec 3, 2015: JCB Laboratories LLC, 5 observations. PDF
- Oct 23, 2015: Pine Pharmaceuticals, 5 observations. PDF
- Jul 11, 2015: Kings Park Slope Inc., 8 observations. PDF
- Nov 19, 2014: Absolute Pharmacy, LLC, 12 observations. PDF
- Oct 17, 2014: California Pharmacy & Compounding Center, 3 observations. PDF
- Mar 27, 2014: US Compoundinq Inc Street 1270 Don's Lane, 8 observations. PDF
FDA links 734 Form 483 PDFs for pharmacies and outsourcing facilities with pages here. 476 are read and shown (FDA posted a few twice; each counts once). 247 are not: 39 are scanned images with no readable text, 127 have numbered observations that could not be read reliably, 80 have a cover FEI and firm name that match no page here by the rule, and 1 could not be downloaded. See the methodology.
Common questions
Which 483s are counted?
Every Form 483 in this index whose cover gives the type of establishment inspected as an outsourcing facility: 186 documents. 483s for 503A pharmacies are counted on the all-483s index page instead.
Does a more common theme mean a bigger problem?
No. The counts show how often FDA investigators wrote about a subject, not how serious any one observation was. A 483 is not a final FDA determination; FDA decides on any action after reviewing the inspection.
Why can one observation count under two themes?
Many statements cover two subjects, such as “Aseptic processing areas are deficient regarding the system for monitoring environmental conditions”, which matches both the sterility and the environmental monitoring patterns. The rule counts it under each matching theme, so theme counts add up to more than the number of observations.
These are FDA investigators’ inspectional observations, quoted from FDA’s published Form 483s. Theme counts come from a keyword rule, not from reading each observation, and are not a finding by this site. Report an error or add a company response.
Sources
- FDA: FDA Form 483 Frequently Asked Questions
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
Records last pulled Nov 15, 2026. Every entry links to the original public record.